Olvimulogene nanivacirepvec
Phase 3Gene therapy
Olvimulogene nanivacirepvec is one of 11 biologic programs targeting Platinum-resistant Ovarian Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Platinum-Resistant Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Avastin
RochePhase 3
SYS6043
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
N-803
IImmunityBio, Inc.
Phase 2
Olvimulogene nanivacirepvec
GGenelux Corporation
Phase 3
M-CENK
IImmunityBio, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immune Checkpoint Inhibitor1 trial
Platinum-resistant Ovarian Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olvimulogene nanivacirepvec. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Gene therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- GGenelux Corporation